靶向色氨酸代谢用于结核生物标志物与宿主导向治疗
综述指出,结核感染上调宿主IDO1,使色氨酸向犬尿氨酸代谢增加,血浆犬尿氨酸/色氨酸比值升高且有效治疗后逆转,可作诊断与疗效生物标志物;犬尿氨酸及下游代谢物促进免疫抑制微环境,非人灵长类IDO抑制显示宿主导向治疗潜力。
要点
- 血浆犬尿氨酸/色氨酸比值在结核病中升高,有效治疗后逆转,可作潜在诊断与疗效标志物。
- 犬尿氨酸及下游代谢物在结核肉芽肿中促进免疫抑制微环境,可能助免疫逃逸。
- 非人灵长类IDO抑制增加T细胞向肉芽肿核心迁移、降低细菌负荷和免疫病理。
核心结论
- 靶向色氨酸-犬尿氨酸代谢通路有望用于结核诊断生物标志物和宿主导向治疗。
- 需开展创新的生物标志物和宿主导向治疗试验来验证其潜力。
研究设计与样本
- 综述,汇总动物和人类研究证据,未报告系统检索范围与样本量。
主要发现
- 动物和人类研究显示,结核分枝杆菌感染上调宿主IDO1,使色氨酸代谢为犬尿氨酸增加。
- 结核病中血浆犬尿氨酸/色氨酸比值升高,有效抗结核治疗后可逆转。
- 犬尿氨酸及下游代谢物在结核肉芽肿中促进免疫抑制微环境,可能利于免疫逃逸。
- 非人灵长类IDO抑制显示肉芽肿核心T细胞迁移增加、细菌负荷降低、免疫病理减轻。
关键数值与推荐
- 血浆犬尿氨酸/色氨酸比值在结核病中升高、有效治疗后逆转,显示作为潜在诊断和治疗生物标志物的效用。
- 非人灵长类IDO抑制展示增加T细胞向肉芽肿核心迁移、降低细菌负荷和减少免疫病理。
临床怎么用
- 可关注血浆犬尿氨酸/色氨酸比值作为结核诊断与疗效监测的潜在生物标志物。
- IDO抑制作为宿主导向治疗策略,需临床试验进一步验证其安全性和有效性。
局限性
- 综述未报告系统检索范围、样本量及具体效应值,证据多来自动物和人类观察性研究。
- exploiting色氨酸-犬尿氨酸通路的生物标志物和宿主导向治疗试验尚需开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Greater understanding of the role of tryptophan metabolism in the immune response to tuberculosis (TB) has provided promising avenues to explore new diagnostic and therapeutic modalities. Animal and human studies have demonstrated that host indoleamine 2,3-dioxygenase 1 (IDO1) is upregulated in response to infection with Mycobacterium tuberculosis, resulting in increased tryptophan metabolism to kynurenine. In TB disease, this is evidenced by elevation of the plasma kynurenine to tryptophan ratio, which is reversed with effective TB treatment, thus showing utility as a potential diagnostic and therapeutic biomarker. Kynurenine and downstream metabolites promote an immunosuppressive microenvironment in TB granulomas, which may facilitate immune evasion. IDO inhibition in nonhuman primates has highlighted its potential role as host-directed therapy by demonstrating increased T-cell trafficking to the granuloma core, reduced bacterial burden, and decreased immunopathology. To realize the potential of exploiting the tryptophan to kynurenine metabolic pathway, innovative biomarker and host-directed therapy trials are needed.
引用
- Collins JM, Tukvadze N, Kempker RR, et al. Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy. J Infect Dis. 2026. PMID: 41037490. doi:10.1093/infdis/jiaf510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。